Connecta Therapeutics

CONNECTA Therapeutics S.L. is a biotechnology company that develops new treatments for CNS unmet medical needs. The company is initially focus on the clinical development of a new “first-in-class” molecule for the treatment of fragile X syndrome (FXS). FXS is the most common cause of hereditary intellectual disability and there are no therapeutic interventions currently available. The molecule was discovered after evaluating more than 30 molecular and cellular targets. The molecule has been proven, in in vitro tests and in vivo in animal models, to be an excellent neuroplasticity modulator with a great extension profile for other neurodevelopmental disorders (Rett syndrome, Down syndrome and autism spectrum disorders, among others).